These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34547339)

  • 21. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Respirable nanocarriers as a promising strategy for antitubercular drug delivery.
    Mehanna MM; Mohyeldin SM; Elgindy NA
    J Control Release; 2014 Aug; 187():183-97. PubMed ID: 24878180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary delivery of anti-inflammatory agents.
    Ali ME; McConville JT; Lamprecht A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):929-45. PubMed ID: 25534260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled therapeutics for prevention and treatment of pneumonia.
    Safdar A; Shelburne SA; Evans SE; Dickey BF
    Expert Opin Drug Saf; 2009 Jul; 8(4):435-49. PubMed ID: 19538104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.
    Iyer R; Hsia CC; Nguyen KT
    Curr Pharm Des; 2015; 21(36):5233-44. PubMed ID: 26412358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and Inhaled Corticosteroids, with or without Beta Agonists, as Adjuvant Therapy in Community Acquired Pneumonia.
    Helgeson SA; Levitt JE; Festic E
    Acta Med Acad; 2020 Apr; 49(1):9-20. PubMed ID: 32738113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhalation Delivery of Host Defense Peptides (HDP) using Nano- Formulation Strategies: A Pragmatic Approach for Therapy of Pulmonary Ailments.
    Adlakha S; Sharma A; Vaghasiya K; Ray E; Verma RK
    Curr Protein Pept Sci; 2020; 21(4):369-378. PubMed ID: 31889487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug delivery and nanoparticles:applications and hazards.
    De Jong WH; Borm PJ
    Int J Nanomedicine; 2008; 3(2):133-49. PubMed ID: 18686775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
    J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.
    Schneider CS; Xu Q; Boylan NJ; Chisholm J; Tang BC; Schuster BS; Henning A; Ensign LM; Lee E; Adstamongkonkul P; Simons BW; Wang SS; Gong X; Yu T; Boyle MP; Suk JS; Hanes J
    Sci Adv; 2017 Apr; 3(4):e1601556. PubMed ID: 28435870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
    Islam N; Richard D
    Curr Cancer Drug Targets; 2019; 19(3):162-178. PubMed ID: 29793407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent Trends and Applications of Nanostructure-based Drug Delivery in Alleviating Chronic Obstructive Pulmonary Disease (COPD).
    Nagar L; Gulati N; Saini A; Singh S; Gupta G; MacLoughlin R; Chellappan DK; Dua K; Dureja H
    Curr Drug Deliv; 2024 Mar; ():. PubMed ID: 38445696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhaled nitric oxide: clinical applications, indications, and toxicology.
    Troncy E; Francoeur M; Blaise G
    Can J Anaesth; 1997 Sep; 44(9):973-88. PubMed ID: 9305562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy.
    Wang W; Hao Y; Liu Y; Li R; Huang DB; Pan YY
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jan; 13(1):e1654. PubMed ID: 32700465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.
    Kumar V; Rahman M; Gahtori P; Al-Abbasi F; Anwar F; Kim HS
    Expert Opin Drug Deliv; 2021 Jun; 18(6):673-694. PubMed ID: 33295218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary drug delivery: a role for polymeric nanoparticles?
    d'Angelo I; Conte C; Miro A; Quaglia F; Ungaro F
    Curr Top Med Chem; 2015; 15(4):386-400. PubMed ID: 25579350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
    Okuda T; Okamoto H
    Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.
    Wu ZL; Zhao J; Xu R
    Int J Nanomedicine; 2020; 15():9587-9610. PubMed ID: 33293809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nano-inside-micro: Disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung.
    Wanakule P; Liu GW; Fleury AT; Roy K
    J Control Release; 2012 Sep; 162(2):429-37. PubMed ID: 22841795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.